Dabigatran: safer, more effective and easier to use than warfarin.
出版信息
Cardiovasc J Afr. 2009 Sep-Oct;20(5):311-2.
PMID:19907807
Abstract
摘要
相似文献
1
Dabigatran: safer, more effective and easier to use than warfarin.
Cardiovasc J Afr. 2009 Sep-Oct;20(5):311-2.
2
Quality of anticoagulation control in atrial fibrillation.心房颤动抗凝控制的质量
Lancet. 2010 Sep 18;376(9745):935-7. doi: 10.1016/S0140-6736(10)61305-0.
3
Dabigatran in clinical practice.达比加群在临床实践中的应用。
Clin Ther. 2012 Oct;34(10):2051-60. doi: 10.1016/j.clinthera.2012.09.008. Epub 2012 Sep 29.
4
Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.达比加群酯用于非瓣膜性心房颤动的血栓栓塞预防：RE-LY研究及相关子研究并附述评
Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1461-71. doi: 10.1586/14779072.2013.849572. Epub 2013 Oct 23.
5
The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.左心耳封堵术与调整剂量华法林和达比加群酯预防房颤卒中的预算影响比较。
Europace. 2014 Aug;16(8):1131-6. doi: 10.1093/europace/euu038. Epub 2014 Mar 30.
6
Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.达比加群酯（Pradaxa）用于治疗心房颤动。
Nurse Pract. 2011 Sep;36(9):6-7. doi: 10.1097/01.NPR.0000403296.82092.fb.
7
Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.家庭监测口服抗凝剂与达比加群的比较。间接比较。
Thromb Haemost. 2012 Oct;108(4):647-53. doi: 10.1160/TH12-01-0027. Epub 2012 Aug 23.
8
Can we rely on RE-LY?我们能信赖RE-LY研究吗？
N Engl J Med. 2009 Sep 17;361(12):1200-2. doi: 10.1056/NEJMe0906886. Epub 2009 Aug 30.
9
10
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.依度沙班用于预防心房颤动合并生物瓣患者的血栓栓塞
Circulation. 2017 Mar 28;135(13):1273-1275. doi: 10.1161/CIRCULATIONAHA.116.026714. Epub 2017 Feb 16.
Zotero 插件